Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider David Malcom Rodman Sells 11,366 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 11,366 shares of the business's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $14.53, for a total transaction of $165,147.98. Following the completion of the sale, the insider now directly owns 111,686 shares of the company's stock, valued at $1,622,797.58. This represents a 9.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

David Malcom Rodman also recently made the following trade(s):

• On Tuesday, April 1st, David Malcom Rodman sold 55,771 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $15.76, for a total value of $878,950.96.

Mineralys Therapeutics Price Performance

NASDAQ:MLYS traded down $0.15 during trading hours on Friday, hitting $13.35. The company's stock had a trading volume of 382,306 shares, compared to its average volume of 417,708. Mineralys Therapeutics, Inc. has a twelve month low of $8.24 and a twelve month high of $18.38. The stock has a fifty day simple moving average of $12.59 and a 200-day simple moving average of $12.36. The company has a market capitalization of $866.09 million, a P/E ratio of -3.67 and a beta of -0.39.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.02. On average, equities analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new stake in Mineralys Therapeutics during the 4th quarter worth $48,000. ProShare Advisors LLC bought a new stake in shares of Mineralys Therapeutics during the fourth quarter worth about $128,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Mineralys Therapeutics by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company's stock valued at $130,000 after buying an additional 989 shares during the period. GAMMA Investing LLC raised its holdings in Mineralys Therapeutics by 9,602.2% in the 1st quarter. GAMMA Investing LLC now owns 8,829 shares of the company's stock valued at $140,000 after buying an additional 8,738 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Mineralys Therapeutics during the 4th quarter worth approximately $145,000. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on MLYS. The Goldman Sachs Group dropped their price target on Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Guggenheim reiterated a "buy" rating on shares of Mineralys Therapeutics in a research report on Monday, February 24th. Finally, HC Wainwright lifted their price objective on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the company a "buy" rating in a research note on Wednesday, April 2nd.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.